Objective To study the mechanism of Guizhi Fuling Capsule treating in mammary gland hyperplasia by network pharmacology. Methods Using PharmMapper, GeneCards, PubMed, GenCLip 3, and STRING platform to screen mammary gland hyperplasia targets of constituents migrating to blood, we constructed a protein-protein interaction (PPI) network. These targets were imported into the CytoNCA plug-in to calculate the important topological parameters of the PPI network to screen key targets. The ClueGO plug-in was used to analyze the biological process of these key targets, and the DAVID database was used to analyze KEGG pathway enrichment. Results Twelve constituents of constituents migrating to blood of Guizhi Fuling Capsule acted on 197 targets in mammary gland hyperplasia, which included 31 key targets, such as transcriptional and apoptotic proteins AKT1, MAPK1, CASP3, MAPK8, BCL2L1, MDM2, and STAT1, signal transduction proteins SRC, HRAS, HSP90AA1, MAPK14, PIK3R1, MAP2K1, and PTPN11, angiogenesis-related targets EGFR, MMP2, KDR, and NOS3, hormone-related receptors IGF1, ESR1, AR, and IGF1R, inflammatory factor IL2, and oxidoreductase CAT. These targets were enriched in 14 different biological processes, including inositol lipid- mediated signaling, mammary gland epithelium development, cellular response to reactive oxygen species, positive regulation of nitric-oxide synthase biosynthesis, T cell co-stimulation, and VEGF receptor signaling pathway, and regulate signaling pathways such as estrogen, prolactin, apoptosis, PI3K-Akt, VEGF, T cell receptors, TNF, and MAPK. Conclusions Guizhi Fuling Capsule is mainly used for the treatment of mammary gland hyperplasia by restoring the balance of sex hormones and promoting the apoptosis of mammary gland cells, as well as having anti-inflammatory, anti- oxidation, anti-angiogenesis, and other pharmacological effects.